Our fictitious once-monthly biologic for severe asthma, and the canvas for a complete demonstration of what an AI-native pharma brand experience should be. The full property is in the works. Here's a first look, and the series that sets the stage.
Patient support that answers, not navigation mazes. Lumi handles starting, coverage, and what to expect.
An MOA video and personalized education, generated and tailored by audience and moment.
The PA intake automation running behind the scenes. The same build shown in our work samples.
Lumara is not a real medication.
Listen now
An AI-produced competitive intelligence podcast following Lumara's launch into a crowded severe-asthma market. A trailer and eight episodes.
The series overview — an 8-episode, TA-specific competitive intelligence podcast produced by Genflare.
Show notes →A fictional once-monthly biologic with dual IL-5 and IL-13 inhibition, poised to enter a crowded severe-asthma market.
Show notes →The real engine of access: how plans decide who gets preferred, who gets blocked, and what it costs to move tiers.
Show notes →The first-fill moment and early adherence: HUB design, copay policy, and specialty-pharmacy handoffs.
Show notes →How existing brands position their value stories to payers, and what it takes to cut through entrenched positioning.
Show notes →Real-world evidence as the currency of access decisions: exacerbations, persistence, and healthcare utilization.
Show notes →Competitive-intelligence maturity: what top teams track, how fast they learn, and why it matters.
Show notes →Borrowing what works in oncology, migraine, and rare disease, and translating those access innovations to Lumara.
Show notes →The launch integration plan: how a specialty biologic turns strategy into day-one execution.
Show notes →Tell us who you are and we'll let you know the moment the full Lumara experience is live.